Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Blade Therapeutics
South San Francisco, California, United Statesblaide.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Blade Therapeutics is developing oral small-molecule therapies targeting novel pathways in fibrotic and neurodegenerative diseases. Its lead asset, cudetaxestat, a noncompetitive autotaxin inhibitor, is expected to enter Phase 2 clinical trials for idiopathic pulmonary fibrosis. Other pipeline assets remain in preclinical development.
- Therapeutic areas
- OtherPulmonologyGastroenterologyNeurology
- Modalities
- Small moleculeChemical drug
- Industry
- Biotech
02
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of the latest available information.
Beyond the preview
Go deeper on Blade Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blade Therapeutics.